000			02270 a2200685 4500
005			20250517000416.0
264		0	_c20150604
008			201506s 0 0 eng d
022			_a1476-5551
024	7		_a10.1038/leu.2014.305 _2doi
040			_aNLM _beng _cNLM
100	1		_aSandhöfer, N
245	0	0	_aDual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. _h[electronic resource]
260			_bLeukemia _cApr 2015
300			_a828-38 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aDrug Synergism
650	0	4	_aGene Expression Regulation, Leukemic
650	0	4	_aGene Rearrangement
650	0	4	_aHeterocyclic Compounds, 3-Ring _xpharmacology
650	0	4	_aHumans
650	0	4	_aImidazoles _xpharmacology
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMice
650	0	4	_aMyeloid-Lymphoid Leukemia Protein _xgenetics
650	0	4	_aOncogene Proteins, Fusion _xgenetics
650	0	4	_aPhosphatidylinositol 3-Kinases _xgenetics
650	0	4	_aPhosphoinositide-3 Kinase Inhibitors
650	0	4	_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors
650	0	4	_aQuinolines _xpharmacology
650	0	4	_aSignal Transduction
650	0	4	_aSirolimus _xpharmacology
650	0	4	_aSurvival Analysis
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aMetzeler, K H
700	1		_aRothenberg, M
700	1		_aHerold, T
700	1		_aTiedt, S
700	1		_aGroiß, V
700	1		_aCarlet, M
700	1		_aWalter, G
700	1		_aHinrichsen, T
700	1		_aWachter, O
700	1		_aGrunert, M
700	1		_aSchneider, S
700	1		_aSubklewe, M
700	1		_aDufour, A
700	1		_aFröhling, S
700	1		_aKlein, H-G
700	1		_aHiddemann, W
700	1		_aJeremias, I
700	1		_aSpiekermann, K
773	0		_tLeukemia _gvol. 29 _gno. 4 _gp. 828-38
856	4	0	_uhttps://doi.org/10.1038/leu.2014.305 _zAvailable from publisher's website
999			_c24285557 _d24285557